BioSpace News Archive

MeMed announces the appointment of Mr. Ori Hadomi as Chairman of the Board of Directors and Mr. Peter Scheu, as President of MeMed US.

Faron Pharmaceuticals Ltd. announces that based on guidance from the U.S. Food and Drug Administration, hypomethylating agents -refractory or relapsed myelodysplastic syndromes has been selected as the initial indication to advance to Phase 2 in the BEXMAB study investigating bexmarilimab in combination with standard of care.

Yemaachi, the company dedicated to advancing precision oncology research and care in Africa for the benefit of patients everywhere, recently shared findings from a sequencing study in an abstract and poster presentation at the 14th AORTIC International Conference on Cancer in Africa.

BioNxt Solutions Inc. is pleased to report on a successful CPHI pharma conference in Barcelona, Spain, recently attended by BioNxt’s European team.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Instil Bio, Inc. reported two poster presentations at the SITC 2023 Annual Meeting demonstrating that its proprietary CoStimulatory Antigen Receptor platform enhances the activity of CD4+ T cells across multiple axes.

Biotheus Inc. (“Biotheus”) today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.

Galvanize Therapeutics, Inc. unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SITC) conference.

Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy.

Bristol Myers Squibb (NYSE: BMY) today announced that research across the company’s cardiovascular franchise will be presented at the American Heart Association’s (AHA) annual Scientific Sessions, taking place November 11-13, 2023 in Philadelphia, Pennsylvania.